---
schema_version: "secwatch.filing_event.v1"
accession: "0001326110-25-000146"
form_type: "8-K"
ticker: "IBRX"
cik: "0001326110"
company_name: "ImmunityBio, Inc."
filed_at: "2025-12-15T23:59:59+00:00"
generated_at: "2026-05-16T13:11:01.436876+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# ImmunityBio appoints Bruce Wendel to board of directors effective Dec. 12.

## Summary
- Bruce Wendel appointed independent director effective Dec. 12, 2025; term expires at 2026 annual meeting.
- Background includes Abraxis BioScience (commercialized Abraxane, led Celgene acquisition), Bristol-Myers Squibb.
- Receives $50k annual cash retainer plus initial stock option with $300k Black-Scholes value, vesting 1/3 annually over 3 years.
- Previously served on boards of GT BioPharma and Verastem.

## SEC filing metadata
- accession: 0001326110-25-000146
- form_type: 8-K
- ticker: IBRX
- cik: 0001326110
- company_name: ImmunityBio, Inc.
- filed_at: 2025-12-15T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326110/000132611025000146/0001326110-25-000146-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326110/000132611025000146/ibrx-20251210.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326110-25-000146
- JSON: https://secwatch.observer/filing/0001326110-25-000146.json
- Plain text: https://secwatch.observer/filing/0001326110-25-000146.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.